Navigation Links
Milan Fiala, MD, receives 2008 Alzheimer Award
Date:4/28/2008

Milan Fiala, MD, UCLA Orthopedic Hospital, has been chosen as the recipient of the 2008 Alzheimer Award presented by the Journal of Alzheimers Disease in recognition of his outstanding work, "Phagocytosis of amyloid-beta and inflammation: Two faces of innate immunity in Alzheimers disease" by M. Fiala, D.H. Cribbs, M. Rosenthal and G. Bernard (July 2007, JAD 11(4): 457-63). Each year the Associate Editors of the journal select an outstanding article from the previous year's volume for this prestigious award.

I am very grateful for the recognition of our laboratorys work by the Journal of Alzheimers Disease, said Dr. Fiala. This award belongs to all of my collaborators as well.

Dr. Fialas work suggests that Alzheimers disease is a failure of the immune system to keep the brain clear from waste products of neuronal chemistries (the most important waste is called amyloid-beta, in particular oligomeric amyloid-beta in neurons). This concept of Alzheimers disease can be compared to uremia when kidneys fail to clear the uremic waste products of body chemistries. In the brain, clearance of waste is difficult because the transport mechanisms across the brain firewall (called the blood-brain barrier) are restricted. The immune cells have the ability to cross the firewall, clean amyloid-beta and protect neurons, but in patients with Alzheimers disease, these cells somehow lose the ability to keep neurons healthy. In fact, these immune cells may be over-doing the cleaning task and become inflamed, and then cause damage to the brain as they do to an inflamed joint. Fortunately, in parallel with these mechanistic discoveries, Dr. Fialas collaborative research is showing that the immune system of patients can be improved, at least in a test tube, using natural products, such as curcuminoids from turmeric. Therefore, Dr. Fiala is developing a blood test of immune deficiency (so-called amyloid-beta stress test) and new ways of immune treatment as an all-inclusive approach to Alzheimers disease detection and prevention.

We hope that these discoveries will lead to an all-inclusive approach to Alzheimers disease detection at an early stage and improvement of the immune system using immunostimulating therapies (e.g curcuminoids) or anti-inflammatory therapies (similar to those used in joint disorders) according to the state of the immune system., stated Dr. Fiala.

Dr. Fiala is a Research Professor of Orthopaedic Surgery at UCLA, Los Angeles, California. He received his initial training at the University of Charles IV, Prague, Czechoslovakia and his MD degree at the University of Geneva, Switzerland. He obtained a MSc (Epidemiology) from Harvard School of Public Health. He pursued translational research in respiratory, herpes and retroviruses viruses at the University of Washington, the University of Pennsylvania and UCLA, and his work played key role in controlling infections of immunocompromised patients.

In the last decade, Dr. Fiala has developed a modification of the amyloid-beta hypothesis suggesting that the underlying problem of Alzheimers disease patients lies in the defectiveness of the innate immune system to clear amyloid-beta in the brain. Dr. Fialas laboratory is situated in the Orthopaedic Hospital Research Center and includes key UCLA collaborators: John Adams, MD; Martin Hewison, PhD; Philip T. Liu, PhD; Araceli Espinosa-Jeffrey, PhD; Mark J. Rosenthal, MD; John M. Ringman, MD; and research staff including many gifted students. External collaborators include John Cashman, PhD, HBRI, San Diego; Naoyuki Taniguchi, Osaka University; and Albert S. Lossinsky, New Jersey Neuroscience Institute, Edison, New Jersey.

This annual award, generously sponsored by Elan Pharmaceuticals, will be presented to Dr. Fiala at the International Conference on Alzheimers Disease 2008 held in Chicago in July.


'/>"/>

Contact: George Perry
editorial@j-alz.com
210-458-4450
IOS Press
Source:Eurekalert  

Related medicine news :

1. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
2. Houston Northwest Medical Center Receives Prestigious Tenet Circle of Excellence Award
3. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
4. Michael E. DeBakey Receives Congressional Gold Medal
5. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
6. Cadient Group Receives Multiple Awards at 2008 DTC National Advertising Awards
7. The National Exercise & Sports Trainers Association Receives Accreditation of Its Personal Fitness Trainer Certification From the National Commission for Certifying Agencies (NCCA)
8. PainCare Receives Notices From American Stock Exchange
9. UT Southwestern Medical Center receives grant from the Robert Wood Johnson Foundation
10. HealthEdge Receives $13 Million Investment Commitment to Fund Significant Growth
11. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Milan Fiala, MD, receives 2008 Alzheimer Award
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/25/2017)... ... 2017 , ... FCPX users now have the ability to sharpen a desired ... Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical ... tools users can visually see the color range effected with ease all within ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – ... Private has initiated a second print-run of its lavish luxury travel coffee table book. ... open, weighs in at more than six kilos, retails at EUR 1,000 per copy ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of ... critically important that we all are aware of our options and are empowered ... to announce the launch of its newest edition of "Vision and Hearing" in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
Breaking Medicine Technology: